Literature DB >> 453708

Documentation of pulmonary capillary permeability in the adult respiratory distress syndrome accompanying human sepsis.

R R Anderson, R L Holliday, A A Driedger, M Lefcoe, B Reid, W J Sibbald.   

Abstract

Current evidence suggests that pulmonary edema accompanying human sepsis may result either from changes in the serum oncotic and hydrostatic pressures or an increase in the permeability of the pulmonary microvasculature. In this study, we compared the "clearance" of injected 131I-labeled human serum albumin from blood to bronchoalveolar secretions in intubated patients with pulmonary edema secondary to sepsis or myocardial infarction. A significantly increased mean +/- SE clearance of the radionuclide was seen in patients with sepsis (0.34 +/- 0.03 ml per hour) compared to those with myocardial infarction (0.043 +/- 0.008 ml per hour) (P less than 0.001), although both groups had similar degrees of edema on chest radiographs. Because the patients with sepsis had no severe decrease in serum oncotic pressure (18.4 +/- 5.0 mm Hg) or evidence of left heart failure, as determined by the pulmonary wedge pressure (11.0 +/- 6.8 mm Hg), we concluded that the genesis of the pulmonary edema in sepsis was due to an increase in pulmonary microvascular permeability, as measured by the increased clearance of 131I-labeled human serum albumin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 453708     DOI: 10.1164/arrd.1979.119.6.869

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

Review 1.  The use of radionuclide techniques in the assessment of alveolar-capillary membrane permeability on the intensive care unit.

Authors:  D N Hunter; C J Morgan; T W Evans
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

2.  Sulfidopeptide-leukotriene peptidases in pulmonary edema fluid from patients with the adult respiratory distress syndrome.

Authors:  W D Ratnoff; M A Matthay; M Y Wong; Y Ito; K H Vu; J Wiener-Kronish; E J Goetzl
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

3.  Immunohistochemical dynamics of leukotoxin (9,10-epoxy-12-octadecenoic acid) in lungs of rats.

Authors:  W Zhang; M Nagao; T Takatori; K Iwadate; Y Itakura; Y Yamada; H Iwase; T Oono
Journal:  Int J Legal Med       Date:  1995       Impact factor: 2.686

4.  Determinants of diagnostic accuracy in pulmonary scintigraphy for pulmonary capillary protein leak associated with adult respiratory distress syndrome (ARDS): a technical note.

Authors:  J Tatum; H Sugerman; N Perdikaris; R Rehr; T Burke; M Fratkin
Journal:  Eur J Nucl Med       Date:  1989

5.  Noninvasive measurement of pulmonary transvascular protein flux in normal man.

Authors:  A B Gorin; J Kohler; G DeNardo
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  Lung water changes after thermal injury. The effects of crystalloid resuscitation and sepsis.

Authors:  R F Tranbaugh; F R Lewis; J M Christensen; V B Elings
Journal:  Ann Surg       Date:  1980       Impact factor: 12.969

7.  Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome.

Authors:  M A Matthay; W L Eschenbacher; E J Goetzl
Journal:  J Clin Immunol       Date:  1984-11       Impact factor: 8.317

8.  Studies on the pathogenesis of the adult respiratory distress syndrome.

Authors:  W W McGuire; R G Spragg; A B Cohen; C G Cochrane
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

9.  Release of angiotensin converting enzyme by the lung after Pseudomonas bacteremia in sheep.

Authors:  A B Gorin; G Hasagawa; M Hollinger; J Sperry; J Zuckerman
Journal:  J Clin Invest       Date:  1981-07       Impact factor: 14.808

10.  Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium.

Authors:  J F Holter; J E Weiland; E R Pacht; J E Gadek; W B Davis
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.